Singapore eyes biologics manufacturing
|
|
Biologic drugs, particularly monoclonal antibodies (mAbs), are set to account for one third of all drugs on the market by 2010 and drive around 60 per cent of pharma firm revenue growth by this time. Singapore has been heavily investing in developing capabilities in this potentially lucrative market sector, as it keeps its eye on the prize. To assist in this, the country has set up the Bioprocessing Technology Institute (BTI) to develop manpower capabilities and establish cutting-edge technologies relevant to the bioprocess community, Sheo Shanker, head of Biomedical Sciences Group at the Singapore Economic Development Board, told In-PharmaTechnologist.com. “The BTI is now also actively encouraging Western firms to set up bioprocessing operations or develop partnerships with domestic firms in Singapore and is providing incentives for the right companies to do so,” said Shanker. More : in-pharmatechnologist.com |